To evaluate whether the lipolytic effects of systemic nicotine are not only attributed to indirect adrenergic mechanisms, but also to a direct action of nicotine on fat cells. DESIGN: The effect of a systemic nicotine infusion (0.5 mgakgamin for 30 min) on lipolysis in subcutaneous adipose tissue was investigated in situ in 11 non-obese, non-smoking, healthy male subjects under placebo-controlled conditions. MEASUREMENTS: By using microdialysis probes the glycerol levels (lipolysis index) and blood¯ow were monitored locally in subcutaneous adipose tissue. RESULTS: Plasma nicotine levels peaked (7.2 ngaml) at the end of the infusion. Nicotine induced a mean ( AE s.e.) percentage peak increase in adrenaline and noradrenaline plasma levels of 213 AE 30% (P`0.01) and 118 AE 5% (P`0.05), respectively. Nicotine increased venous plasma glycerol levels by 144 AE 9% (P`0.001), arterialized plasma glycerol levels by 148 AE 12% (P`0.001) and adipose glycerol levels by 148 AE 16% (P`0.001), but did not alter blood¯ow. By inducing a local cholinoceptor blockade with mecamylamine (10 75 M) via the microdialysis system, the increase in adipose glycerol levels was inhibited by $ 45% (P 0.02). A corresponding local beta-adrenoceptor blockade with propranolol (10 74 M), inhibited the increase in adipose glycerol levels by $ 60% (P 0.02). Infusion of saline (ie placebo) had no effect on the parameters mentioned above. CONCLUSION: Systemically administered nicotine induces lipolysis, in part by activating the classical adrenergic mechanism (mediated by a nicotine-induced release of catecholamines stimulating beta-adrenoceptors), and in part by directly activating a nicotinic cholinergic lipolytic receptor located in adipose tissue.
Introduction
Nicotine is, apart from alcohol, the most commonly used stimulating agent in many societies. In addition, there is an increasing use of nicotine in pharmacotherapy, for example in stopping smoking programs. The role of tobacco use in the development of atherosclerotic cardiovascular disease is well accepted today. Although the mechanisms responsible for this side effect of smoking are unclear, it is likely that alterations in lipid metabolism caused by the nicotine in tobacco play an important role. 1 Mobilization of free fatty acids through lipolysis in adipose tissue could be involved in these events. 2 Nicotine may in¯uence the fat stores and an increase of body weight is observed in many subjects following stopping smoking. Although a number of factors could contribute to weight gain after smoking cessation 3,4 a decrease in lipid mobilization from adipose tissue could be of particular importance because it directly in¯uences body fat storage.
Catecholamines are the only hormones with a pronounced stimulatory effect on lipolysis in man. This effect is mediated by beta-adrenoceptors on the cell surface of fat cells. 5 It is well established that smoking stimulates lipolysis in vivo. This was ®rst demonstrated by measuring circulating lipid metabolites. 6 There is also direct evidence from results of measurements of the¯ux of fatty acids and glycerol. 7 This lipolytic effect of smoking can be mimicked by intravenous infusions of nicotine reaching circulating nicotine concentrations that are obtained during moderate smoking. 8 Moreover, lipolysis appears to be the most sensitive system to nicotine stimulation among various metabolic, cardiovascular and hormonal systems tested in vivo in man. 8 The lipolytic effect of smoking has been attributed to the nicotine component being mediated via release of catecholamines. Thus, smoking induces an increase of circulating catecholamines and glycerol (lipolysis index), and this glycerol increase is prevented by an adrenergic blockade. 6 In addition, other smoking effects on the cardiovascular system and carbohydrate metabolism have also been attributed to the catecholamineaadrenergic mechanism. 6 A direct effect of nicotine on lipolysis through its own receptors was not considered initially, since cholinergic innervation or receptors have not yet been found on fat cells. Recently, however, a cholinergic regulation of lipolysis was demonstrated in vivo in human adipose tissue involving a direct stimulation of lipolysis via nicotinic cholinoceptors. 9 This was done using microdialysis, which is a relatively new technique for monitoring lipolysis and blood¯ow in situ in adipose tissue by extracting glycerol from the interstitial space. 10 Glycerol is an end product of lipolysis that is not re-utilized by the tissue. Changes in tissue glycerol levels re¯ect production by lipolysis and blood¯ow. 10 Another unique feature of microdialysis is that it can directly study the in situ effect of agents delivered directly to the tissue. We have used the microdialysis method to investigate whether direct cholinergic andaor indirect adrenergic mechanisms are responsible for lipolysis activation in human adipose tissue following systemic administration of nicotine.
Subjects
The experimental group consisted of 11 male healthy subjects. All were non-smoking and non-obese. None were on regular medication. The age ranged from 20 to 32 y, and the body mass index (BMI) ranged from 20.2 to 25.3 kgam 2 (21.9 AE 0.5 kgam 2 , means AE s.e.). The Committee on Ethics at Huddinge Hospital approved the study. The subjects were given a detailed description of the study and their consent was obtained.
All studies were performed with the subject in the supine position at 08:00 h after an overnight fast. A venous catheter was placed in the antecubital vein for blood sampling. The contralateral hand was placed in a temperature-controlled box (63 C) and a catheter was placed in the dorsal hand vein for blood sampling of arterialized blood ( b 95% O 2 -saturation). A vein on the dorsal part of the foot was connected to an infusion pump for infusion of saline or nicotine.
The microdialysis probes (10Â0.5 mm, 20 000 molecular weight cut-off, CMA Microdialysis, Stockholm, Sweden) used have been described in detail elsewhere. 11 Three microdialysis probes were inserted percutaneously without anesthesia into the abdominal subcutaneous adipose tissue on either side of the umbilicus with an inter-distance of 30 mm. The inlet tubing of the probe was connected to a microinjection pump (CMA Microdialysis, Stockholm, Sweden) and was continuously perfused (1.4 mlamin, fraction time 15 min) for 3 h with an ethanol-based (50 nM) Ringer solution, which was composed as described. 16 One probe perfused with this solution alone served as control probe; in the other two probes were either the cholinergic blocking agent, mecamylamine (10 75 M, Sigma Chemical Co., St Louis, MO, USA), or the beta-adrenoceptor blocking agent, ( AE )-propranolol (10 74 M, Pharmacia-Upjohn, Stockholm, Sweden). It was previously demonstrated in microdialysis experiments on human adipose tissue that, using the present concentrations of each blocker it is possible to obtain a local, selective and complete receptor blockade without causing systemic effects. 10 Both blockers are easily water-soluble and their molecular weight is only about one-hundredth of the molecular weight cut-off of the dialysis membrane. Therefore, they are assumed to diffuse freely through the microdialysis membrane. The treatments given were infused in random order, with regard to probe position on each side of the umbilicus, in the different subjects. Dialysate glycerol, as well as ethanol, was analyzed, and the ratio of ethanol leaving vs entering was determined. Changes in this ratio re¯ect changes in the nutritive blood¯ow of the adipose tissue. 10, 12 The method gives similar results to the so-called xenon-washout technique. 13 The coef®cients of variations for the baseline levels of glycerol and ethanol ratio were 10 and 5%, respectively.
The subjects rested in the supine position for 60 min before starting the experiment. During this period the subjects received the intravenous saline infusion, and the microdialysis probes were perfused with the solvent, mecamylamine or propranolol solutions, respectively. During the ®rst 30 min of the experiment, the subjects continued to receive the saline infusion and basal measurements were made of the different parameters. The experiment was continued with a 30 min nicotine (0.5 mgakgamin, Swedish Tobacco Group, Stockholm, Sweden) intravenous infusion, and ended with a 90 min saline infusion period. In a separate run saline infusion was given instead of nicotine to four individuals and these served as placebo-controlled experiments. In two subjects the saline treatment experiment was carried out before the nicotine experiment and in two subjects the nicotine experiment was run before the nicotine experiment. The volunteers were not informed before the start of experiment which treatment was to be performed. Blood and dialysate samples were taken, and systolic and diastolic blood pressure, and heart rate were measured every 15 min throughout the 2 h experiment. No side-effects were reported by the volunteers during saline infusion. Very modest side-effects were reported during the nicotine infusion. Two subjects mentioned a mild feeling of slight dizziness, two subjects mentioned a mild feeling of peripheral coldness, and one volunteer showed slight paleness but without reporting any side-effects. The remaining six volunteers did not report or demonstrate any side-effects.
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In total the side-effects were very mild and in no cases did the experiment have to be ended due to side-effects. Plasma nicotine and cotinine levels were analyzed using capillary gas chromatography as described previously. 8, 14 The detection limit for nicotine and cotinine was 0.2 and 1.3 ng, respectively. The sample volume was 0.5 ml. Plasma levels of adrenaline and noradrenaline were determined by the hospital routine chemistry laboratory. Dialysate and plasma glycerol, and dialysate ethanol levels were determined as described elsewhere. 8, 12 Values (mean AE s.e.) for plasma nicotine, cotinine, and heart rate, systolic and diastolic blood pressure are given in absolute numbers. Values (mean AE s.e.) for glycerol, adrenaline and noradrenaline are presented as a percentage of the mean values during the ®rst 30 min of the experiment, which represents a pre-experimental baseline value. Values (mean AE s.e.) for ethanol are presented as the percentage ratio between the outgoing and ingoing concentration in the perfusion solvent. Statistical comparison was made between saline and nicotine treatments using Student's ttest, because only two groups of values were compared. Statistical comparison between the solvent probes in saline and nicotine treated groups and the mecamylamine and propranolol probes in the nicotine treated group was made by analysis of variance (ANOVA), using Fischer's PLSD test for post-hoc analysis, because more than two groups (ie three) of values were compared. P`0.05 was set as level for statistical signi®cant difference. The time-dependent changes following nicotine treatment were statistically analyzed for the different parameters using ANOVA, giving the respective Pvalues within parentheses.
Results
Plasma nicotine and cotinine levels Plasma levels of nicotine and cotinine before, during and after intravenous nicotine (0.5 mgakgamin for 30 min) infusion are shown in Figure 1 . The mean ( AE s.e.) plasma nicotine levels increased to 7.2 AE 0.8 ngaml (P`0.001, ANOVA for the time-course) during the nicotine infusion followed by a gradual decline, although they were still increased by 50% of the peak levels 90 min after termination of infusion. Plasma cotinine levels continuously increased with time throughout the experimental period (P`0.001, ANOVA for the time-course).
Pulse rate and blood pressure Nicotine treatment increased the systolic blood pressure from 112 AE 1.4 to 121 AE 1.5 mmHg (P`0.001, ANOVA for the time-course), the diastolic blood pressure from 75 AE 1.7 to 81 AE 1.5 mmHg (P`0.001, ANOVA for the time-course), and the pulse rate from 58 AE 1.4 to 69 AE 2.8 beatsamin (P`0.001, ANOVA for the time-course) at the end of the 30 min infusion, followed by a gradual decline during the post-infusion period (Figure 2) . When comparing the percentage changes induced by intravenous nicotine treatment from intravenous saline treatment (ie placebo), signi®cant increases were found on all three parameters during the infusion period (Figure 2 ).
Plasma adrenaline and noradrenaline
Nicotine treatment increased adrenaline and noradrenaline levels, measured in venous blood, from 0.20 AE 0.04 to 0.50 AE 0.21 nmolal (P`0.01, ANOVA for the time-course) and from 1.05 AE 0.11 to 1.20 AE 0.13 nmolal (P`0.05, ANOVA for the time-course), respectively, during the nicotine infusion (Figure 3 ). During the post-infusion period the plasma adrenaline and noradrenaline concentrations gradually declined. When comparing the percentage changes induced by intravenous nicotine treatment from intravenous saline treatment (ie placebo), signi®cant increases were found, particularly in adrenaline levels but also to a minor extent in noradrenaline levels during the infusion period ( Figure 3) .
A similar increment in adrenaline (from 0.20 AE 0.03 to 0.45 AE 0.12 nmolal; P`0.001) and noradrenaline (from 0.91 AE 0.09 to 1.05 AE 0.09 nmolal; P`0.05) plasma levels was also found in corresponding arterialized blood samples during the nicotine infusion (data not shown).
Plasma and microdialysate glycerol
The results on glycerol in plasma and microdialysate are shown in Figure 4 . Arterialized and venous plasma glycerol levels (lipolysis index) increased and peaked to similar levels (148 AE 12 and 144 AE 9%, respectively) during the 30 min intravenous nicotine infusion, and declined during the Systemic nicotine and lipolysis K Andersson and P Arner post-infusion period. Thus, mean ( AE s.e.) venous plasma glycerol levels rose from 40 AE 5 to 55AE 5 mmolal (P`0.001, ANOVA for the time-course), and mean ( AE s.e.) arterialized plasma glycerol levels rose from 36 AE 5 to 51AE 6 mmolal (P`0.001, ANOVA for the time-course). During the intravenous infusion period the nicotine-treated group was Figure 2 Effects of intravenous saline or nicotine (0.5 mgakgamin) infusion for 30 min on systolic blood pressure (top panel), diastolic blood pressure (middle panel) and heart rate (bottom panel). Values (means AE s.e.) are expressed as a percentage of baselines. In the saline group, systolic blood pressure 100% 114 AE 2.0 mmHg, diastolic blood pressure 100% 74 AE 3.1 mmHg, heart rate 100% 66 AE 3.8 beats per min; n 4. In the nicotine treated group, systolic blood pressure 100% 112 AE 1.4 mmHg, diastolic blood pressure 100% 75 AE 1.7 mmHg, heart rate 100% 58 AE 1.4 beatsamin; n 11. Statistical comparison was made using Student's t-test; *P`0.05.
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signi®cantly different from the saline treated (ie placebo) group (Figure 4) . By using microdialysis probes the interstitial glycerol levels were monitored within the subcutaneous adipose tissue. Before saline or nicotine infusion the mean glycerol levels in the probe used in the intravenous saline experiment and the control, mecamylamine or propranolol probes used in the intravenous nicotine experiment were similar, ie 30 AE 5, 30 AE 4, 33 AE 4 and 31 AE 5 mmolal, respectively. In the nicotine experiment the dialysate glycerol levels in control probe increased by 148 AE 16% and peaked at 45 min after onset of infusion (P`0.001, ANOVA for the time-course). When the nicotinic cholinoceptor antagonist, mecamylamine (10 75 M), was present in the microdialysate, a signi®-cant increase (peak levels 132 AE 11%; P`0.001, ANOVA for the time-course) during nicotine infusion was still observed. However, the increase in dialysate glycerol levels was signi®cantly lower as compared to that observed in the control probe (P 0.02, two-way ANOVA followed by post-hoc analysis revealed that values for control probe differed from values in mecamylamine probe at 15, 30, 60, 75 and 90 min after starting nicotine infusion).
When the beta-adrenoceptor antagonist, propranolol (10 74 M), was present in the microdialysate, a signi®cant increase (peak levels 117 AE 5%; P`0.001, ANOVA for the time-course) during nicotine infusion was still observed. Also, the increase in dialysate glycerol levels was signi®-cantly lower as compared to that observed in the control probe (P 0.02, two-way ANOVA followed by post-hoc analysis revealed that values for control probe differed from values in propranolol probe from 15 min until 75 min after starting nicotine infusion). No statistically signi®cant difference was found between the mecamylamine and the propranolol probes.
There was no change over time in the microdialysate glycerol levels following intravenous saline infusion (ie placebo).
Ethanol dialysate ratio
No changes in local adipose tissue blood¯ow (as measured with the ethanol escape technique) could be recorded before, during and after the saline or nicotine infusion as judged from the respective solvent microdialysis probes ( Figure 5 ). Neither addition of mecamylamine nor propranolol to the microdialysis probes altered the local tissue blood¯ow ( Figure 5 ).
Discussion
This placebo controlled study presents evidence for a new mode of action of systemic nicotine on lipolysis in man. Smoking or oral use of tobacco, introduces nicotine into the circulation. Nicotine can also be administered by chewing gums and plaster when it is used to prevent ex-smokers from relapses. It was previously shown that smoking induces an enhancement of circulating adrenaline and noradrenaline levels, which was associated with an increased lipolysis. 6 The effects of the cigarette smoke on body weight and on the metabolic events are generally attributed to nicotine, which is further supported by our recent ®ndings demonstrating that systemic nicotine infusion dose-dependently increases circulating catecholamines (primarily adrenaline), and glycerol and free fatty acids. 8 The presently used dose of nicotine produced plasma nicotine levels in the order of 7 ngaml. This is in the lower range of what is observed following smoking one cigarette. 15 After terminating the nicotine infusion there was a multi- Figure 3 Effects of intravenous saline or nicotine infusion on circulating venous adrenaline and noradrenaline levels. In the saline group, all adrenaline levels were below the detection limit of 0.1 nmolal, noradrenaline 100% 1.1 AE 0.3 nmolal; n 4. In the nicotine group, adrenaline 100% 0.2 AE 0.04 nmolal, noradrenaline 100% 1.05 AE 0.11 nmolal; n 11. See legend to Figure 2 for details.
Systemic nicotine and lipolysis K Andersson and P Arner exponential decline of plasma nicotine levels, and the main nicotine metabolite, cotinine, increased continuously throughout the experiment, as reported earlier. 8 In a previous study, 6 it was shown that smoking produced a marked rise in adrenaline ( $ 250%), and a moderate increase in noradrenaline ( $ 140%) plasma levels. Our present ( Figure 2 ) and previous 8 ®ndings that the nicotine infusion markedly increased adrenaline ( $ 250%) and moderately increased noradrenaline ( $ 115%) plasma levels supports the concept that it is the nicotine component of tobacco that causes the catecholamine release.
As discussed earlier, 6 the increase in metabolic events induced by the cigarette smoke seems to be caused by the circulating catecholamines, since adrenergic blockade prevented the increases. In agreement with a postulated role of the nicotine component of the smoke, the acute nicotine infusion produced a sustained increase in plasma glycerol levels. The highest levels were observed at the end of the Figure 4 The effects of an intravenous saline or nicotine infusion (horizontal line) on plasma venous and arterialized glycerol concentrations (top panel), and on dialysate glycerol concentrations in adipose tissue (bottom panel). Top panel: saline, venous blood 100% 42 AE 10 mmolal; saline, arterialized blood 100% 38 AE 7 mmolal, n 4; nicotine, venous blood 100% 40 AE 5 mmolal; nicotine, arterialized blood 100% 36 AE 5 mmolal; n 11. Bottom panel: saline probe 100% 30 AE 5 mmolal; n 14. Nicotine treatment solvent probe 100% 30 AE 4 mmolal, mecamylamine probe 100% 33 AE 4 mmolal, and propranolol probe 100% 31 AE 5 mmolal; n 12. Statistical comparison was made between saline and nicotine treatments using Student's t-test. Statistical comparison between the saline, mecamylamine and propranolol probes in the nicotine treated group was made by analysis of variance, using Fischer's PLSD test for post-hoc analysis, *P`0.05.
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K Andersson and P Arner 30 min infusion period ( Figure 3 ). By means of microdialysis, the adipose tissue glycerol levels were monitored locally. They were increased by the nicotine infusion to the same order of magnitude as in plasma. Local production plus removal by tissue circulation may both contribute to the changes in dialysate glycerol levels. However, no changes in ethanol ratio could be observed during the microdialysis experiment, indicating that local changes in adipose tissue blood¯ow were not interfering with the nicotine-induced changes in glycerol levels. Thus, the observed increases in adipose glycerol levels were most likely due to an activation of adipocyte lipolysis. The increase in glycerol levels in the microdialysis probe during the nicotine infusion could be prevented by adding either propranolol ( $ 60% blockade) or mecamylamine ( $ 45% blockade) to the microdialysate. These drugs create a local beta-adrenergic and nicotinic cholinergic blocking environment, respectively. It is conceivable that both mecamylamine and propranolol, due to their molecular size, should rapidly diffuse into the surrounding extracellular interstitium of the probe, thus producing an inhibition of local nicotinic cholinoceptors and adrenoceptors, respectively. The exact concentrations of nicotine (derived from the intravenous infusion) or mecamylamine (derived from the probe) in the monitored region of the probe are impossible to measure. It is also not possible to measure the local adipose tissue concentrations of nicotine-induced adrenaline from the adrenal glands and locally nicotine-induced release of noradrenaline in relation to propranolol concentrations in the vicinity of the probe. It should be noted, however, that a complete inhibition of lipolysis was not obtained here using any of the two antagonists, although previous studies showed that a maximal selective receptor blockade is obtained by the concentrations presently used of the blockers. 9, 16 Maintenance of lipolysis stimulation by nicotine with selective blockade (propranolol or mecamylamine) is to be expected, if the adrenergic and cholinergic receptor systems each contribute to the nicotine effect. Unfortunately, it was not possible for technical reasons to add more probes in order to study possible interactions between nicotine and mecamylamine. Furthermore, we could not use more potent nicotine receptor blockers for safety reasons because they have not been used previously in vivo on man. However, there was no evidence of cross-over reactivity at the respective adrenergic and cholinergic receptors when propranolol and mecamylamine were used in microdialysis experiments with human adipose tissue. 9 The glycerol peak in the microdialysis probe occurred later than in plasma. This may be due to plasma glycerol levels re¯ecting lipolysis in all adipose regions as opposed to the local registration obtained with microdialysis. A marked regional variation in lipolysis rate is well known. 17 In addition, muscle lipolysis could contribute to plasma glycerol levels. 18 Taken together, the present results favour the view that two separate mechanisms are responsible for regulating lipolysis induced by systemically administered nicotine. One is the classical mechanism that, via a catecholamine release, induces lipolysis by stimulation of beta-adrenoceptors located on the fat cell. By an additional mechanism, nicotine itself induces lipolysis by activating the recently demonstrated local nicotinic cholinergic receptors in the adipose tissue. 9 It is plausible that the smoking-induced changes in lipolysis also use these two mechanisms. The present results may seem at odds with some earlier ®ndings about the effects of nicotine on lipolysis measured by microdialysis. Eliasson and collegues observed no lipolysis activation from cigarette smoking or following administration of an equal amount of nicotine given as a nasal spray. 19 In our opinion methodological factors may explain the different Systemic nicotine and lipolysis K Andersson and P Arner ®ndings. The previous study was not placebo-controlled and was performed on smokers. We investigated non-smokers under placebo-controlled conditions.
The physiological relevance of nicotinic receptors for regulation of lipolysis may be questioned in view of the limited evidence for a cholinergic innervation of adipose tissue, as discussed previously. 20, 21 A direct action of acetylcholine is less conceivable since there is no evidence of cholinergic receptors on the fat cell, and no effects of nicotine on glycerol release was observed in human subcutaneous fat cells incubated in vitro. 9 The release of paracrine lipolytic agents originating from endothelial cells of capillaries was suggested to substantiate an indirect regulation of lipolysis. 9 It may still be argued that cholinoceptors in adipose tissue are dormant receptors with insigni®cant physiological role in the normal human due to the lack of cholinergic innervation. However, these receptors seem to be activated by systemic nicotine administration, which may have clinical implications when considering the pathophysiological effects of nicotine use. A relationship between tobacco use and atherosclerotic cardiovascular disease has been ®rmly established, although the responsible mechanisms are largely unknown. 1 It is, though, quite possible that increased lipid metabolism is involved in the atherosclerosic process, bearing in mind the role of free fatty acids themselves. 2 Nicotine-induced metabolic changes are also clinically relevant for the problems in stopping smoking such as weight gain. In the present study we have presented evidence of a local nicotinic cholinergic receptor mechanism, which together with the classical adrenergic mechanism contributes to the lipid metabolic events following systemically given nicotine.
